Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | CDK8 | P49336 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | MUSK | O15146 | 1/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549118 | 0.90 | RAF1 (0.65) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL548163 | 0.88 | RAF1 (0.64) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL548126 | 0.87 | RAF1 (0.56) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL15114775 | 0.80 | KDR (0.58) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL29746649 | 0.80 | KDR (0.58) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL29733289 | 0.79 | RAF1 (0.67) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL548256 | 0.79 | RAF1 (0.67) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL548328 | 0.78 | RAF1 (0.79) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL14481108 | 0.77 | RAF1 (0.60) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL3181311 | 0.77 | RAF1 (0.70) | RAF1KDRCDK8CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181188-B2 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2015-11-10 | — | — | US | claimed |
| US-20120136157-A1 | ARYL UREAS AS KINASE INHIBITORS | DUMAS JACQUES (US) | 2012-05-31 | — | — | US | claimed |
| EP-1580188-B9 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-23 | — | — | EP | claimed |
| US-8110587-B2 | Antiinflammatory agents; anticancer agents; osteoporosis | BAYER HEALTHCARE LLC (US) | 2012-02-07 | — | — | US | claimed |
| EP-1580188-B1 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2011-10-19 | — | — | EP | claimed |
| JP-4527401-B2 | — | — | 2010-08-18 | — | — | JP | claimed |
| EP-1580188-A1 | Aryl ureas as kinase inhibitors | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | claimed |
| JP-2005523278-A | — | — | 2005-08-04 | — | — | JP | claimed |
| EP-1474393-A1 | ARYL UREAS AS KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-11-10 | — | — | EP | claimed |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | BAYER CORPORATION (US) | 2003-11-20 | — | — | US | claimed |
| WO-2003068746-A1 | ARYL UREAS AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| US-9181188-B2 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20120136157-A1 | ARYL UREAS AS KINASE INHIBITORS | DUMAS JACQUES (US) | 2012-05-31 | — | — | US | disclosed |
| EP-1580188-B9 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8110587-B2 | Antiinflammatory agents; anticancer agents; osteoporosis | BAYER HEALTHCARE LLC (US) | 2012-02-07 | — | — | US | disclosed |
| EP-1580188-B1 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-1580188-A1 | Aryl ureas as kinase inhibitors | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1474393-A1 | ARYL UREAS AS KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | BAYER CORPORATION (US) | 2003-11-20 | — | — | US | disclosed |
| WO-2003068746-A1 | ARYL UREAS AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K6 | RAF1 47/4885KDR 40/4885CDK8 158/4885 |
| US-20120136157-A1 | ARYL UREAS AS KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K6 | RAF1 47/4885KDR 40/4885CDK8 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.